Image source- The Statesman
US researchers have discovered that oral drugs can be much more beneficial in stopping tumors from growing further.
He added, “It is a receptor that surveils the intercellular compartment of a cell, looking for danger molecules or pathogens.”
He also said, “When NLRP3 recognizes these signals, it leads to the activation of caspase-1, a protein involved in the processing and maturation of interleukin-1-beta into its biologically active form, causing an intense inflammatory response. We found that in melanoma, this process is dysregulated, resulting in tumor growth.”
PNAS journal :
This complete study is published in the PNAS journal.
The oral NLRP3 :
The oral NLRP3 inhibitor, which is used in the study, has already shown results it is much more effective in clinical trials, in recovering gout and heart disease. It is currently being tested in Covid-19 as well.
All the researchers are currently trying to find that if the NLRP3 inhibitor can be successfully used in melanoma patients.
Carlo Marchetti told :
Marchetti said, “Checkpoint inhibitors increase the efficacy of the immune system to kill tumors, but sometimes tumors become resistant to this treatment.” He added, “A big part of cancer research now is to find therapies that can be combined with checkpoint inhibitors to improve their efficacy.”